Group 1 - Zhengrong Real Estate (06158.HK) has appointed joint liquidators by its controlling shareholder, and trading of its shares will resume from 9 AM on Wednesday, with business operations continuing as usual [1] - XPeng Motors (09868.HK) plans to hold a board meeting on May 21 to approve its first-quarter results [1] - Xiehe New Energy (00182.HK) reported a total equity generation of 3,330.69 GWh in the first four months, a year-on-year decrease of 2.24%, with April's generation at 809.84 GWh, down 6.48% year-on-year [1] Group 2 - Touyun Biotechnology (01332.HK) plans to sell 70% of its stake in Weidao International for 13 million yuan [1] - Gilead Sciences (01672.HK) will present early research findings on its obesity candidate drug ASC47 at the 32nd European Congress on Obesity (ECO 2025) through oral and poster presentations [1] - Yuanda Pharmaceutical (00512.HK) has successfully reached clinical endpoints in its Phase II clinical study of the global innovative product STC3141 for the treatment of sepsis in China [1] Group 3 - Shanggao New Energy (01250.HK) reported a cumulative operational generation of approximately 1.0196 million MWh in the first two months, representing a year-on-year increase of about 13.1% [1]

Group 1: Hong Kong Monetary Authority Actions - The Hong Kong Monetary Authority (HKMA) intervened twice in the market, selling a total of 127.88 billion HKD (approximately 16.50 billion USD) to maintain the Hong Kong dollar's peg to the US dollar, following an earlier sale of 605.43 billion HKD (approximately 78.12 billion USD) [1] - HKMA President Yu Weiwen noted that the demand for the Hong Kong dollar is rising, primarily driven by stock-related needs, and there are no signs of abnormal activity in the currency [1] - The HKMA has reduced the duration of its holdings in US Treasury bonds and is diversifying its investments into non-US assets to manage risks [1] Group 2: Financial Market Trends - The US stock market saw declines, with the Dow Jones falling by 389.83 points (0.95%) to 40,829.00 points, and the Nasdaq dropping by 154.58 points (0.87%) to 17,689.66 points [2] - Spot gold prices rose above 3,400 USD for the first time in two weeks, influenced by geopolitical tensions between Pakistan and India [2] - Crude oil futures for June delivery increased by 1.96 USD, closing at 59.09 USD per barrel, marking a rise of 3.43% [2] Group 3: Financial Policy Announcements - The State Council of China will hold a press conference to introduce a package of financial policies aimed at stabilizing the market and expectations [3] Group 4: Hong Kong Stock Exchange Initiatives - The Hong Kong Stock Exchange and the Securities and Futures Commission have launched a "Special Line for Science and Technology Enterprises" to facilitate the listing process for technology and biotech companies, allowing them to submit applications confidentially [4] Group 5: Trade Relations and Tariffs - The European Union plans to impose additional tariffs on approximately 1 trillion EUR worth of US goods if ongoing trade negotiations do not yield satisfactory results [5] Group 6: Postal and Delivery Industry Performance - During the "May Day" holiday, China's postal and express delivery industry handled over 4.8 billion packages, reflecting a year-on-year growth of over 20%, marking a historical high for the same period [6][7] Group 7: Aviation Industry Insights - During the "May Day" holiday, domestic flight operations exceeded 68,000 flights, with a year-on-year increase of about 3%, while international flights saw a 12% increase [8] Group 8: Cross-Border Travel Statistics - The Gongbei border checkpoint reported a record average daily passenger flow of nearly 380,000 during the "May Day" holiday, with a total of nearly 1.9 million travelers, a year-on-year increase of 21.5% [9] Group 9: Restaurant Industry Performance - Haidilao restaurants experienced high customer traffic during the "May Day" holiday, with some locations achieving a table turnover rate exceeding 12 times [10] Group 10: Corporate Acquisitions - Zhongchuang Innovation plans to invest nearly 1.2 billion RMB to acquire a 22.61% stake in Suao Sensor, indicating strategic expansion in the sensor technology sector [11] Group 11: Robotics Industry Developments - Yujian and others have become shareholders in Zhongke Fifth Epoch, a company involved in the development of intelligent robotics and AI applications [12] Group 12: Hydrogen Energy Sector Expansion - Beijing Tianhai Hydrogen Energy Equipment Co., a subsidiary of Jingcheng Electromechanical, plans to raise capital through equity expansion to enhance market competitiveness [13] Group 13: Pharmaceutical Innovations - Yuanda Pharmaceutical's global innovative product STC3141 has successfully reached clinical endpoints in a Phase II trial for treating sepsis in China, marking significant progress in critical care research [14] Group 14: Obesity Treatment Research - Gilead Sciences will present research results on its obesity candidate drug ASC47 at the European Obesity Congress, highlighting advancements in obesity treatment [15]

遠大醫藥集團有限公司* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 董事會欣然公告，本集團全資擁有附屬公司 Grand Medical Pty Ltd.（一間本集團在 澳洲設立的創新藥研發中心）開發的全球創新藥物 STC3141，在中國開展的用於治 療膿毒症的 II 期臨床研究成功達到臨床終點，該臨床研究進度處於全球膿毒症研究 領域前列，這是本集團在危重症領域的又一重大研發進展。同時，STC3141 是全球 首個以重新構建免疫穩態為核心的膿毒症治療方案，實現了治療維度的重大升級， 在現有的抗感染、液體復蘇和維持器官運轉等對症支持治療的基礎上，針對機體免 疫失調這個核心病因加以精准調節，幫助身體恢復平衡，填補了當前膿毒症針對病 因治療的臨床空白。這次臨床研究的成功有望推動膿毒症治療邁入一個新紀元。 -1- 該研究是一項評估靜脈輸注 STC3141 注射液在膿毒症患者中的療效、安全性 ...

Core Viewpoint - The successful completion of the Phase II clinical trial for STC3141 by YuanDa Pharmaceutical marks a significant advancement in the treatment of sepsis, demonstrating both efficacy and safety, and positioning the company at the forefront of global sepsis research [1][2][3]. Clinical Development - STC3141 is a novel small molecule compound developed by YuanDa Pharmaceutical, targeting the immune dysregulation in sepsis through a unique mechanism [2][3]. - The Phase II trial involved 180 sepsis patients and assessed the efficacy, safety, and pharmacokinetics of STC3141, with primary endpoints focusing on changes in the SOFA score [2][3]. - Results showed a significant reduction in SOFA scores in the treatment group compared to the placebo, particularly in the high-dose group, indicating both statistical and clinical significance [3]. Market Potential - Sepsis is a major global health challenge, with a high mortality rate of 25%-60%, and approximately 50 million cases annually worldwide, leading to over 11 million deaths [4]. - The global market for sepsis treatment is projected to grow from approximately $3.814 billion in 2024 to $5.967 billion by 2031, with a CAGR of 6.7% from 2025 to 2031 [4]. - In China, there are about 2.5 million sepsis patients annually, with over 700,000 deaths, highlighting a significant unmet clinical need [4]. Competitive Landscape - Currently, there are no specific drugs available for sepsis treatment, presenting a unique opportunity for pharmaceutical companies to develop targeted therapies [5]. - YuanDa Pharmaceutical has established a strong position in the critical care sector, with a comprehensive product portfolio and ongoing research in unmet clinical needs [6][9]. Future Outlook - The successful trial of STC3141 not only reinforces YuanDa Pharmaceutical's R&D capabilities but also positions the product as a potential breakthrough therapy in sepsis treatment [3][9]. - The company plans to engage with regulatory authorities to expedite the approval process for STC3141, aiming to address the urgent clinical needs of sepsis patients [3][9].

远大医药公告，集团全资附属公司Grand Medical Pty Ltd.开发的全球创新药物STC3141在中国开展的用 于治疗脓毒症的II期临床研究成功达到临床终点。该临床研究入组了180名接受标准治疗和护理的脓毒 症患者，持续给药5天，并随访至第28天。研究的主要临床终点指标为第7天序贯器官衰竭评估(SOFA) 评分较基线的变化值，次要终点包括第7天SOFA评分较基线下降幅度达到25%的受试者比例、第3天和 第5天SOFA评分较基线的变化值、28天全因死亡率等。结果显示，药物治疗组第7天SOFA评分较基线均 有明显下降，尤其是高剂量组，降幅明显大于安慰剂组。此外，STC3141安全性、耐受性良好，药代动 力学特征也符合预期。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願性公告 本集團全球創新產品 STC3141 在中國開展的 II 期臨床研究成功達到臨床終點 本公告乃遠大醫藥集團有限公司(「本公司」，連同其附屬公司統稱「本集團」)之 董事會(「董事會」)自願刊發。 董事會欣然公告，本集團全資擁有附屬公司 Grand Medical Pty Ltd.（一間本集團在 澳洲設立的創新藥研發中心）開發的全球創新藥物 STC3141，在中國開展的用於治 療膿毒症的 II 期臨床研究成功達到臨床終點，該臨床研究進度處於全球膿毒症研究 領域前列，這是本集團在危重症領域的又一重大研發進展。同時，STC3141 是全球 首個以重新構建免疫穩態為核心的膿毒症治療方案，實現了治療維度的重大升級， 在現有的抗感染、液體復蘇和維持器官運轉等對症支持治療的基礎上，針對機體免 疫失調這個核心病因加以精准調節，幫助身體恢復平衡，填補了當前膿毒症針對病 因治療的臨床空白。這次臨床研究的成功有望推動膿 ...

港股创新药ETF（159567）紧密跟踪港股通创新药指数（987018），该指数反映港股通生物科技产业上 市公司的运行特征。 华福证券表示，医药生物行业我们持续看好创新+复苏+政策三大主线。其中，创新药械为产业周期最 为明确，我们"寻增量"策略的核心方向，收入和利润正逐步体现，2205年多个企业有望盈利。看好有出 海竞争力的创新Biopharma、有创新第二增长曲线的Pharma及创新药配套产业链CXO。 国金证券表示，创新药独立行情贯穿全年。医药板块中最值得关注的仍将是创新药赛道，我们认为对创 新医药投资机会的把握将是贯穿2025年全年医药投资的主线，在当前时点重点看好创新药出海龙头和仿 创结合龙头，同时积极关注会议数据发布和海外BD商务合作进程。 （本文机构观点来自持牌证券机构，不构成任何投资建议，亦不代表平台观点，请投资人独立判断和决 策。） （文章来源：21世纪经济报道） 5月6日，港股创新药板块早盘走强，港股创新药ETF（159567）一度涨超2.2%，截至发稿涨1.35%，成 交额超7000万元，换手率超5%，早盘交投活跃。 成分股中，远大医药、先声药业、亚盛医药-B涨超2%，百济神州、复星医药、 ...

Investment Rating - The industry investment rating is "stronger than the market" [3][47]. Core Viewpoints - The approval of Ivosidenib for first-line treatment of NSCLC in China is a significant milestone, being the first to show positive results in a clinical trial comparing it to Pembrolizumab [3]. - The HARMONi-2 trial demonstrated that Ivosidenib significantly improved progression-free survival (mPFS of 11.14 months vs. 5.82 months for Pembrolizumab), with a hazard ratio (HR) of 0.51, indicating a 49% reduction in the risk of disease progression or death [3]. - The interim analysis of overall survival (OS) at 39% maturity showed a 22.3% reduction in mortality risk for Ivosidenib compared to Pembrolizumab (HR=0.777) [3]. Summary by Sections Industry News - Ivosidenib has received approval for a new indication in first-line treatment of PD-L1 positive locally advanced or metastatic NSCLC based on the HARMONi-2 trial results [3]. - The trial involved a randomized comparison of Ivosidenib and Pembrolizumab, with primary endpoints focused on progression-free survival (PFS) [3]. - Additional studies have shown Ivosidenib's efficacy in various NSCLC settings, including in combination with chemotherapy [4]. Investment Strategy - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [6]. - Companies to watch include innovative drug developers and those with strong overseas market potential, such as BeiGene, Dongcheng Pharmaceutical, and others [6]. Key Companies to Watch - **Nocera Healthcare**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year growth in sales [7]. - **Sihuan Pharmaceutical**: Strong fundamentals with a stable growth outlook, particularly in the ADC market [10]. - **China Biopharmaceutical**: Rapid revenue growth with a focus on innovative products, particularly in oncology [11]. - **Aier Eye Hospital**: Benefiting from increasing demand for eye care services and a strong pipeline of new products [20].

Policy Developments - The State Council, led by Premier Li Qiang, has discussed and approved the draft of the Medical Security Law, aiming to enhance the medical security policy system and protect the rights of insured individuals [2] - The draft emphasizes the need for stricter supervision of medical insurance funds and the establishment of mechanisms to combat fraudulent medical practices [2] Legislative Updates - The third review of the Infectious Disease Prevention Law revision has been conducted, which includes provisions for timely clarification of false or incomplete infectious disease information by health authorities [3] - The revision also calls for strengthening the disease prevention and control capabilities of medical institutions [3] Regulatory Actions - The National Medical Products Administration (NMPA) has suspended the import of digoxin raw materials from VITAL LABORATORIES PVT. LTD. due to discrepancies in production processes and quality management [4] - The NMPA has mandated that any products made with the affected raw materials must not be released into the market [4] Company Announcements - Weishinkang has received a drug registration certificate for its compound amino acid injection, which is intended for patients with renal insufficiency [6] - Yiling Pharmaceutical's subsidiary has received approval for the listing of letrozole, a drug used in breast cancer treatment [7] Financial Reports - Yixin Tang reported a 79.23% decline in net profit for 2024, with revenues of 18 billion yuan and a net profit of 114 million yuan [9] - Kexing Pharmaceutical's net profit for Q1 2025 increased by 106.21%, with revenues of 354 million yuan [10] - Shengda Bio's Q1 2025 net profit surged by 469.35%, reaching 21.71 million yuan [11] Capital Market Developments - Synaire has completed a multi-million yuan angel round of financing, which will be used for product development and global brand expansion [13] Industry News - The NMPA has identified 10 batches of cosmetics containing banned ingredients, prompting investigations and required corrective actions from involved companies [15] - Tsinghua University has established an AI hospital, aiming to integrate AI with medical services and education [16] - Yuan Da Pharmaceutical's early detection product for urinary tumors has received FDA breakthrough device designation and has commenced clinical application [17] Shareholder Actions - Shareholders of Xiangsheng Medical plan to reduce their holdings by up to 1.72% of the company's shares [19]

Core Viewpoint - Early diagnosis and intervention in cancer treatment is a primary policy direction in China, as highlighted by the "Healthy China Action - Cancer Prevention and Control Action Implementation Plan (2023-2030)" which emphasizes promoting early diagnosis and treatment of cancer and strengthening screening mechanisms [1] Company Developments - On April 27, 2023, the Hong Kong-listed innovative pharmaceutical company, Yuan Da Pharmaceutical (00512), announced the commercialization of its early detection product, Youai®, for urinary system tumors in collaboration with Beijing Xiangxin Biotechnology Co., Ltd. This product is the only approved dual-mechanism early detection product for urothelial carcinoma in China, marking a significant advancement in non-invasive tumor diagnostics [1][3] - Youai® has received multiple recommendations from authoritative guidelines, including the "2024 CSCO Urothelial Carcinoma Diagnosis and Treatment Guidelines" and the "Bladder Cancer Early Diagnosis and Treatment Expert Consensus (2024 Edition)" [3] - The product demonstrates a sensitivity of 92.5% and specificity of 95.8% based on over 1,000 clinical studies, significantly improving patient comfort compared to invasive procedures like cystoscopy [3] Market Potential - The early detection market for tumors in China is projected to grow significantly, with a compound annual growth rate of 97.9% from 2018 to 2022, reaching approximately 28.5 billion yuan by 2030 [4] - The demand for precise and non-invasive early detection of urinary system tumors is substantial, given the increasing incidence of these cancers, with over 270,000 new cases reported in 2020 [5] Product Pipeline and Innovation - Yuan Da Pharmaceutical is advancing its product pipeline in the nuclear medicine sector, with 15 innovative products under development, covering various radioactive isotopes and multiple cancer types [6][9] - The company has established a comprehensive industrial layout in the nuclear medicine field, including research, production, sales, and regulatory qualifications, aiming to solidify its position as a leader in the global nuclear medicine oncology market [9]